论文信息 - Growth hormone therapy in hypochondroplasia - 字舞流文

Growth hormone therapy in hypochondroplasia

Ramaswami U, Hindmarsh PC, Brook CGD. Growth hormone therapy in hypochondroplasia. Acta Pædiatr 1999; Suppl 428: 116–17. Stockholm. ISSN 0803–5326

U. Ramaswami | C. Brook | P. Hindmarsh

[1] P. Hindmarsh,et al. Genotype and phenotype in hypochondroplasia. , 1998, The Journal of pediatrics.

[2] P. Hindmarsh,et al. Final height of short normal children treated with growth hormone , 1996, The Lancet.

[3] D. Donoghue,et al. Constitutive activation of fibroblast growth factor receptor 3 by the transmembrane domain point mutation found in achondroplasia. , 1996, The EMBO journal.

[4] P. Prinos,et al. A common FGFR3 gene mutation in hypochondroplasia. , 1995, Human molecular genetics.

[5] D. Church,et al. Mutations in the transmembrane domain of FGFR3 cause the most common genetic form of dwarfism, achondroplasia , 1994, Cell.

[6] P. Hindmarsh,et al. Growth and Growth Hormone Therapy in Hypochondroplasia , 1990, Acta paediatrica Scandinavica.

[7] J M Tanner,et al. Standards from birth to maturity for height, weight, height velocity, and weight velocity: British children, 1965. II. , 1966, Archives of disease in childhood.

[8] J. Tanner,et al. Standards from birth to maturity for height, weight, height velocity, and weight velocity: British children, 1965. I. , 1966, Archives of disease in childhood.

[9] I. Kaitila,et al. A recurrent mutation in the tyrosine kinase domain of fibroblast growth factor receptor 3 causes hypochondroplasia , 1995, Nature Genetics.

[10] C. Brook,et al. Progress report: growth hormone in skeletal dysplasia. , 1994, Hormone research.